- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01134666
An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer
Studieoversigt
Detaljeret beskrivelse
Cetuximab, a chimeric immunoglobulin G1 (IgG1) monoclonal antibody, has been found to potentiate the effects of chemotherapy and radiotherapy in experimental systems. The findings from clinical trials suggest a favorable risk-benefit ratio of the combination of irinotecan or oxaliplatin, infusional 5-FU/FA and biweekly cetuximab, and support the current study to demonstrate the therapeutic value of the biweekly cetuximab regimen as a combination partner for those regimens in subjects with KRAS wild-type mCRC in the first-line setting. The purpose of this study is to generate post marketing surveillance (PMS) data for cetuximab in first-line mCRC, which is mandated by the Licensing Authorities.
This is an open-label, non-randomized, prospective, multicentric Phase IV study evaluating FOLFIRI/ FOLFOX plus cetuximab in the first-line therapy of subjects with KRAS wild-type metastatic CRC. The study plans to enroll 100 subjects with KRAS wild type CRC at 20 centres across India. Tumour status, physical and laboratory examinations will be performed during the baseline visit. Subjects will be administered FOLFIRI/ FOLFOX and cetuximab according to the clinical condition in the following treatment visits. Regular safety assessments and all adverse events (AEs) will be documented throughout and until the end-of-study visit. The outcome of AEs ongoing at the final tumour assessment visit will be followed up at the end-of-study visit (If possible, 6 weeks after the last administration of study medication but before second-line anticancer treatment, and not earlier than 30 days after the end of study treatment). Skin toxicity present at the end-of-study visit will be followed up until outcome is known.
OBJECTIVES
Primary Objective:
- To evaluate the safety and tolerability of Cetuximab in combination with standard chemotherapy such as FOLFOX or FOLFIRI as first-line therapy of patients with KRAS wild-type metastatic colorectal cancer.
Secondary Objective:
- To evaluate the efficacy of Cetuximab in combination with standard chemotherapy as first-line therapy of patients with KRAS wild-type metastatic colorectal cancer.
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
-
Delhi, Indien, 110055
- Nothern Railway Central Hospital
-
Delhi, Indien, 110076
- Indraprastha Apollo Hospital
-
Delhi, Indien, 110092
- Shanti Mukand Hospital
-
Delhi, Indien, 110096
- Dharamshila Cancer Hospital & Research Centre
-
-
Andhra Pradesh
-
Hyderabad, Andhra Pradesh, Indien, 500034
- Indo- American Cancer Institute & Research Centre
-
Hyderabad, Andhra Pradesh, Indien, 500063
- NVS Ramakrishna's Clinic
-
Secunderabad, Andhra Pradesh, Indien, 500025
- Dr. Nikhil's Clinic
-
Secunderabad, Andhra Pradesh, Indien, 500025
- Nikhil Gharyalpatil's Clinic
-
-
Andrapradesh
-
Hyderabad, Andrapradesh, Indien, 500001
- Ravi Kumar's Clinic
-
Hyderabad, Andrapradesh, Indien, 500008
- Ambaa Hospitals
-
Hyderabad, Andrapradesh, Indien, 500059
- Swarna Sai Hospital
-
-
Bangalore
-
Mangalore, Bangalore, Indien, 575 001
- Manipal Centre For Clinical Research
-
-
Calicut
-
Kerala, Calicut, Indien, 673016
- Medical College Calicut
-
-
Gujarat
-
Ahmedabad, Gujarat, Indien, 380009
- Hemato Oncology Clinic
-
-
Karnataka
-
Hubli, Karnataka, Indien, 580020
- Kattimani Oncology Clinic
-
-
Kashmir
-
Srinagar, Kashmir, Indien, 190001
- SKIMS
-
Srinagar, Kashmir, Indien, 190010
- S. K. I. M. S.
-
-
Madhya Pradesh
-
Bhopal, Madhya Pradesh, Indien, 462001
- Dr. T. P. Sahoo's Clinic
-
-
Maharashtra
-
Mumbai, Maharashtra, Indien, 400014
- BND Onco Centre
-
Mumbai, Maharashtra, Indien, 400071
- Joy Hospital
-
Pune, Maharashtra, Indien, 411001
- Ruby Hall Clinic
-
-
Mizoram
-
Aizwal, Mizoram, Indien, 796 009
- Grace Nursing Home
-
-
Mumbai
-
Bandra, Mumbai, Indien, 400050
- Lilavati Hospital
-
Mahim, Mumbai, Indien, 400016
- S.L.Raheja Hospital
-
-
New Delhi
-
Delhi, New Delhi, Indien, 110044
- Apollo Cancer Institute
-
Delhi, New Delhi, Indien, 110085
- Rajiv Gandhi Cancer Institute & Research
-
-
Punjab
-
Amritsar, Punjab, Indien, 143004
- Fortis Escorts Hospital
-
Chandigarh, Punjab, Indien, 160101
- Dr. Rajeev Bedi's Clinic
-
Ludhiana, Punjab, Indien, 141001
- D.M.C Hospital
-
Mohali, Punjab, Indien, 160071
- IVY Hospital
-
-
Rajasthan
-
Jaipur, Rajasthan, Indien, 302004
- SMS Hospital
-
Jaipur, Rajasthan, Indien, 302004
- Cancer Clinic
-
Jaipur, Rajasthan, Indien, 302006
- Bhagwan Mahaveer Cancer Hospital
-
Jaipur, Rajasthan, Indien, 302030
- Bhagwan Mahaveer Cancer Hospital & Research Centre
-
Jodhpur, Rajasthan, Indien, 3420003
- Vyas Cancer Care
-
-
Tamilnadu
-
Trivandrum, Tamilnadu, Indien, 695011
- TC 14/ 764 Sreemangalam
-
-
Uttar Pradesh
-
Ghaziabad, Uttar Pradesh, Indien, 201014
- Shati Gopal Hospital
-
Lucknow, Uttar Pradesh, Indien, 226007
- Annapurna Medical and Cancer Relief Society
-
-
West Bengal
-
Kolkata, West Bengal, Indien, 700026
- Chittaranjan National Cancer Institute
-
Kolkata, West Bengal, Indien, 700054
- Apollo Gleneagles Cancer Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Subjects with histologically confirmed, adenocarcinoma of the colon or rectum (mCRC)
- Subjects with KRAS wild-type status of tumour tissue
- Chemotherapy naïve subjects
- Subject who have signed written informed consent (as per institutional protocol)
Exclusion Criteria:
- As per summary of product characteristics of cetuximab
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Safety and tolerability evaluated based on the incidence and severity of AEs.
Tidsramme: From baseline to follow-up visit for any ongoing AEs
|
From baseline to follow-up visit for any ongoing AEs
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Response rate
Tidsramme: Baseline to End-of-Study Visit
|
Disease Control Rate (DCR), Progression Free Survival (PFS)and Overall Survival (OS)
|
Baseline to End-of-Study Visit
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Studieleder: Rajiv Rana, MD, Merck Ltd., India
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i fordøjelsessystemet
- Neoplasmer efter sted
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Gastrointestinale sygdomme
- Tyktarmssygdomme
- Tarmsygdomme
- Intestinale neoplasmer
- Endetarmssygdomme
- Neoplasmer
- Kolorektale neoplasmer
- Antineoplastiske midler
- Antineoplastiske midler, immunologiske
- Cetuximab
Andre undersøgelses-id-numre
- EMR 062202-517
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Kolorektale neoplasmer
-
Guangzhou First People's HospitalAfsluttet
-
University of ArkansasAktiv, ikke rekrutterendeColorectal cancer og inflammatorisk tarmsygdomForenede Stater
-
University Health Network, TorontoAstraZenecaAktiv, ikke rekrutterendeAdenocarcinom i bugspytkirtlen | Leiomyosarkom | Mismatch Reparation Proficient Colorectal CancerCanada
-
Tianjin Medical University Cancer Institute and...RekrutteringMSI-H Advanced Colorectal CancerKina
-
Bristol-Myers SquibbAktiv, ikke rekrutterendeMikrosatellit stabil kolorektal cancer | Mismatch Reparation Proficient Colorectal Cancer | Mikrosatellit ustabil kolorektal cancer | Mismatch Reparation Manglende tyktarmskræftForenede Stater, Australien, Belgien, Canada, Irland, Italien, Spanien, Frankrig
-
Syndax PharmaceuticalsMerck Sharp & Dohme LLCAfsluttetMelanom | Ikke-småcellet lungekræft | Mismatch Reparation-Proficient Colorectal CancerForenede Stater
Kliniske forsøg med Cetuximab
-
University Medical Center GroningenUMC Utrecht; Erasmus Medical CenterRekrutteringPlanocellulært karcinom i hoved og hals | MarginvurderingHolland
-
Amsterdam UMC, location VUmcRadboud University Medical Center; University Medical Center GroningenAfsluttetMetastatisk tyktarmskræftHolland
-
West China HospitalFirst Affiliated Hospital of Chongqing Medical UniversityRekrutteringColo-rektal cancer | Capecitabin | CetuximabKina
-
Eben RosenthalNational Cancer Institute (NCI)AfsluttetAdenocarcinom i bugspytkirtlenForenede Stater
-
HiberCell, Inc.AfsluttetKolorektal cancerForenede Stater, Puerto Rico, Tyskland, Frankrig
-
Merck KGaA, Darmstadt, GermanyAfsluttetTidligere ubehandlet metastatisk tyktarmskræftFrankrig, Italien, Polen, Tyskland, Hong Kong, Østrig, Brasilien, Israel, Grækenland, Argentina, Thailand, Belgien, Australien, Mexico
-
Arbeitsgemeinschaft medikamentoese TumortherapieMerck Sharp & Dohme LLCAfsluttet
-
Gruppo Oncologico del Nord-OvestAfsluttetMetastatisk tyktarmskræftItalien
-
Cancer Institute and Hospital, Chinese Academy...Rekruttering
-
Universitaire Ziekenhuizen KU LeuvenMerck KGaA, Darmstadt, GermanyAfsluttetKolorektal cancerSpanien, Frankrig, Belgien, Ungarn, Østrig